KayoThera, a Seattle, WA-based early-stage therapeutics company advancing novel cancer immunotherapies, raised $8M in Series A funding.
The round was led by Accelerator Life Science Partners (“ALSP”) with participation from BioAdvance and 7G Bioventures.
The company intends to use the funds to expand their development efforts.
Co-founded in 2019 and based on research conducted by Mark Esposito, PhD and Yibin Kang, PhD at Princeton University, KayoThera is an early-stage therapeutics company focused on the development of a new class of cancer immunotherapeutics to treat late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers.
Dr. Kang is a Warner-Lambert/Parke-Davis Professor of Molecular Biology. Dr. Esposito is a postdoctoral research associate in the Kang lab.
FinSMEs
18/03/2022